Journal articles: 'Antacids'

1

Ramadan, Mai, and Saba Turk. "Assessment of the Acid Neutralizing Capacity and Other Properties of Antacid Formulations Marketed in the Gaza Strip." Israa University Journal for Applied Science 6, no. 2 (April 1, 2023): 97–110. http://dx.doi.org/10.52865/qchr1551.

Full text

Abstract:

Background: Antacids are frequently used as over-the-counter (OTC) medications to reduce symptoms of dyspepsia and to neutralize stomach acidity. Evaluation of antacids efficacy depends on in vitro testing like acid neutralizing capacity (ANC) and acid neutralization potential (ANP). The purpose of this study was to examine ANC, ANP, and other characteristics of commercially available antacid formulations (both liquid and solid formulations) in the Gaza Strip. Methods: Both liquid (n=2) and solid (n=4) antacid formulations were acquired from the Gaza Strip’s central community pharmacies. Preliminary antacid test (PAT) was carried out to determine if the tested formulation is classified as antacid. The general monograph <301> in USP34/NF29 was used for the estimation of ANC, while ANP was investigated using Rossett Rice procedure. Both tests were conducted to evaluate the efficacy of antacid. In addition, cost effectiveness per formulation and statistical analysis test of data were calculated. Results: All formulations were classified as antacids because they all passed the PAT test (pH of antacid-HCl over 3.5). The ANC of antacids (n=6) varied from 8.74±0.37 to 29.14±0.84 mEq per minimum labeled dose (MLD). The ANC/MLD ratios for solid formulations were higher than those of liquid formulations. No statistically significant difference in ANC/MLD between the two groups was estimated (P˃.0.05). ANP test - the time duration during which an antacid formulation maintains pH above 3.5 - ranged from 43 to 90 minutes. According to this study liquids were inefficient in acid neutralization and expensive as a result. Conclusions: The ANC and ANP results indicated the better neutralizing efficacy and duration of solid antacids in comparison to liquids. A1 and A2 formulations– calcium and magnesium salt based solid antacids had the most appropriate properties in terms of efficacy, onset and duration of neutralizing activity. Antacids in the form of chewable tablets were the most cost-effective formulations. It is recommended to examine more batches of the same antacids and to add ANC data on the label of antacids.

APA, Harvard, Vancouver, ISO, and other styles

2

Sutphen, James L., Vivian L. Dillard, and Mary E. Pipan. "Antacid and Formula Effects on Gastric Acidity in Infants With Gastroesophageal Reflux." Pediatrics 78, no. 1 (July 1, 1986): 55–57. http://dx.doi.org/10.1542/peds.78.1.55.

Full text

Abstract:

A variety of peptic diseases are treated with antacids. Antacid dose requirements for young children have not been extensively evaluated. Moreover, the effects of formula feedings on antacid requirements are also unknown. We have investigated the effects of antacids and formula feedings on gastric acidity in infants less than 1 year of age. Small formula feedings of 15 mL/kg per feeding significantly improve antacid buffering of 0.5 mL/kg per dose of standard magnesium-aluminum hydroxide antacids.

APA, Harvard, Vancouver, ISO, and other styles

3

Garg, Vandana, Prashant Narang, and Ritu Taneja. "Antacids revisited: review on contemporary facts and relevance for self-management." Journal of International Medical Research 50, no. 3 (March 2022): 030006052210864. http://dx.doi.org/10.1177/03000605221086457.

Full text

Abstract:

Heartburn and acid regurgitation are the typical symptoms of gastroesophageal reflux. Despite the availability of several treatment options, antacids remain the mainstay treatment for gastroesophageal reflux-related symptoms based on their efficacy, safety, and over-the-counter availability. Antacids are generally recommended for adults and children at least 12 years old, and the FDA recommends antacids as the first-line treatment for heartburn in pregnancy. This narrative review summarizes the mechanism, features, and limitations related to different antacid ingredients and techniques available to study the acid neutralization and buffering capacity of antacid formulations. Using supporting clinical evidence for different antacid ingredients, it also discusses the importance of antacids as OTC medicines and first-line therapies for heartburn, particularly in the era of the COVID-19 pandemic, in which reliance on self-care has increased. The review will also assist pharmacists and other healthcare professionals in helping individuals with heartburn to make informed self-care decisions and educating them to ensure that antacids are used in an optimal, safe, and effective manner.

APA, Harvard, Vancouver, ISO, and other styles

4

DEB, SIDDHARTHA. "Antacid Poisoning." Pediatrics 86, no. 2 (August 1, 1990): 325. http://dx.doi.org/10.1542/peds.86.2.325.

Full text

Abstract:

To the Editor.— Dr J. Brand and Dr F. Greer's discussion of a case of hypermagnesemia and intestinal perforation following antacid administration in a premature infant1 can be misleading to physicians who may need to use antacids for treating their patients. The patient in consideration was receiving 18 mL/kg/d of antacids. This is equivalent to more than a liter of antacids per day for an average adult weighing 60 kg. The management of bleeding of the upper gastrointestinal tract would include the use of H2 receptor blocking agents and usually 2 to 4 mL of antacids or more per kg per day to keep the gastric pH value above 5. Hence, the complications in the baby discussed are secondary to massive overdosage and toxicity of the antacids and to not following routine antacid administration.

APA, Harvard, Vancouver, ISO, and other styles

5

Boya, Dina, and Jwan Ahmed. "Comparison of Acid-neutralizing capacity of antacids in Erbil City." Zanco Journal of Medical Sciences 25, no. 2 (August 11, 2021): 586–90. http://dx.doi.org/10.15218/zjms.2021.023.

Full text

Abstract:

Background and objective: Antacids are basic substances that can neutralize hydrochloric acid and reduce gastric acidity. They are over the counter drugs used to treat dyspepsia. The most commonly used antacids are sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, and calcium carbonate. This study aimed to evaluate the effectiveness of antacids that are commonly used in Erbil city by finding their acid-neutralizing capacity. Methods: The method for acid-neutralizing capacity was adapted from pharmacopeia. The samples were prepared by dissolving the antacid in an excess amount of hydrochloric acid, then neutralizing the excess acid with sodium hydroxide solution by doing back titration. The number of milliequivalents that are neutralized by the antacid is the acid-neutralizing capacity of the antacid. Results: Rennie® chewable tablet showed the highest acid-neutralizing capacity, followed by AntacidAwa and Maalux® plus. The lowest acid-neutralizing capacity was for the suspensions Gaviscon® and Enoxon®. Conclusion: Acid-neutralizing capacity is an easy and quick method to evaluate the efficacy of antacids. Different combinations of salts and concentrations can affect the acid-neutralizing capacity of the antacid. The higher the neutralizing effect of the antacid, the more effective the antacid is. Keywords: Acid-neutralizing capacity; Antacid; pH; Dyspepsia; Erbil.

APA, Harvard, Vancouver, ISO, and other styles

6

Parakh, Rajendra Kumar, and Neelakanth S. Patil. "Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy." International Journal of Research in Medical Sciences 6, no. 2 (January 24, 2018): 383. http://dx.doi.org/10.18203/2320-6012.ijrms20180005.

Full text

Abstract:

Anaesthetic antacids, combination of antacids (Aluminium hydroxide, Magnesium hydroxide) with an anaesthetic (oxethazaine), is becoming a choice of physicians and is re-emerging across all types of GI disorders (esophagitis, peptic ulcer, duodenal ulcer, heartburn, gastritis, functional dyspepsia), despite the discovery of potent and efficacious acid suppressants like H2 receptor blockers and proton pump inhibitors (PPIs). The reason being that anaesthetic antacids increase the gastric pH and provide relief from pain for a longer period of duration at considerably a lower dosage. Furthermore, it significantly increases the duration between the time of medication and the peak pH as compared to antacid alone. Oxethazaine, an anaesthetic component, produces a reversible loss of sensation and provides a prompt and prolonged relief of pain, thereby broadening the therapeutic spectrum of antacids. Antacids vary widely in their in vitro acid neutralizing capacity (ANC), which measures the potency. Among marketed brands in India, Digecaine has shown the highest potency with maximum mean ANC value (28.84 mEq). The expert panel has recommended the inclusion of oxethazaine-antacid/alginate-antacid as complementary to the proton pump inhibitors in the management algorithm of gastroesophageal reflux disease. The present review summarizes the pharmacokinetic and pharmacodynamic of different components of anaesthetic antacids and its clinical use across different gastrointestinal indications, for generalists and specialists, based on existing evidences.

APA, Harvard, Vancouver, ISO, and other styles

7

Watts, D. W. "In Vitro Buffering Capacities of Proprietary Non-Particulate Antacids Available in New Zealand." Anaesthesia and Intensive Care 22, no. 2 (April 1994): 184–86. http://dx.doi.org/10.1177/0310057x9402200212.

Full text

Abstract:

Four commercially available non-particulate antacid preparations were titrated against 1M hydrochloric acid to assess buffering capacity as compared to 30 ml 0.3M sodium citrate solution. All antacids were used in the manufacturers “unit dose”. All antacids tested demonstrated some in vitro buffering capacity, and “Eno” (Reckitt and Colman) had a buffering capacity similar to that of sodium citrate. The retail cost per unit dose was established for each proprietary antacid and for sodium citrate. It was concluded that while proprietary antacids are cheaper per dose than sodium citrate, preparations differ in their acid-neutralising capacity.

APA, Harvard, Vancouver, ISO, and other styles

8

Benjamin U Ebeshi, Samuel J Bunu, Hilda F Kpun, and Cynthia O Ezebube. "Analysis of gastrointestinal acid-neutralizing potency of some commercial antacid tablet formulations." GSC Biological and Pharmaceutical Sciences 19, no. 2 (May 30, 2022): 008–13. http://dx.doi.org/10.30574/gscbps.2022.19.2.0159.

Full text

Abstract:

In dyspepsia, formulations known as antacids are regularly used to alleviate symptoms as quickly as possible. Gastric contents are acidic; therefore, antacids are usually weak bases with the potential to neutralize excess acid and raise gastric pH accordingly. Acid-neutralizing capacity is what determines the effectiveness of an antacid. Some antacid tablets formulation from different manufacturers were tested for their acid-neutralizing capacity and effectiveness for patients in this study. The South-East region of Nigeria had pharmacies vending antacids of different brands. To remove potential bias from the study, the brands were coded A-F. Labels on all samples indicated that they would expire more than one year from now. To determine each antacid tablet's acid-neutralizing capacity, the titrimetric method was used. In terms of acid-neutralizing capacity, brands D, A, B, C, F, and E showed the greatest acid-neutralizing capacity (8.2mEq/g), and brand E showed the lowest capacity (5.7 mEq/g). An analysis of the ANC of all the tablets found that they exceeded the FDA standard of >5mEq for antacids. An inexpensive, simple, and easy-to-use titrimetric method could be used routinely to monitor antacid tablet quality.

APA, Harvard, Vancouver, ISO, and other styles

9

Plotnikova, E. Y., and L. G. Vologzhanina. "Antacids and their role in treatment of digestive diseases in pregnant women." Herald of Pancreatic Club 47, no. 2 (April 29, 2020): 82–88. http://dx.doi.org/10.33149/vkp.2020.02.10.

Full text

Abstract:

Antacids are drugs that can neutralize or buffer the hydrochloric acid of the stomach without affecting its production. History of the clinical use of antacids dates back several centuries. The article discusses the advantages and disadvantages of modern antacids, provides a classification of drugs of this group, considers the mechanisms of their action, explains the term “acid-neutralizing activity”, lists indications for the use of antacids and possible adverse effects of antacid therapy. The results of various foreign and domestic studies on the use of acid-suppressive drugs, including antacids, are presented. Currently, antacids continue to be used for the symptomatic treatment of certain acid-dependent diseases, including gastroesophageal reflux disease (GERD). Due to a number of physiological reasons, GERD often worries pregnant women, most often in the third trimester of pregnancy. The choice of acid-suppressing agents in pregnant women is extremely limited, because the possibility of prescribing any drugs in this category of patients is determined by the safety of the drug, its tolerability, and the absence of teratogenic effects. Features of the mechanism of action of antacids, their favorable pharmacological properties determine the possibility of using modern combined drugs of this group during pregnancy. Relieving heartburn in pregnant women through the use of non-absorbable combined antacids is supported by the FDA, the European guidelines for the treatment of GERD. The article lists antacid drugs registered in the pharmaceutical market, special attention is paid to drugs approved for use during pregnancy.

APA, Harvard, Vancouver, ISO, and other styles

10

Okhuelegbe, Eraga Sylvester, Idemili Nwachukwu Osita, and Iwuagwu Magnus Amara. "In vitro interaction between Zidovudine and some adsorptive antacids." Dhaka University Journal of Pharmaceutical Sciences 13, no. 1 (February 2, 2015): 1–6. http://dx.doi.org/10.3329/dujps.v13i1.21853.

Full text

Abstract:

The in vitro interaction between zidovudine and three antacids and a commercial product was investigated. The extent of adsorption of zidovudine by the antacids, and the effects of the antacids on the disintegration time and dissolution of the drug from tablets were studied. Adsorption of the drug by the antacids followed the order; magnesium trisilicate > aluminium hydroxide > magnesium hydroxide. Retardation of dissolution amongst the antacids and commercial product was of the order; Jawasil® > magnesium trisilicate > aluminium hydroxide > magnesium hydroxide. Also, the degree of retardation of dissolution from the tablets increased as the amount of adsorbent increased. Co-administration of zidovudine and adsorptive antacid formulations should be avoided in clinical practice since it can lead to a decrease in the bioavailability of zidovudine, ultimately leading to therapeutic failure. DOI: http://dx.doi.org/10.3329/dujps.v13i1.21853 Dhaka Univ. J. Pharm. Sci. 13(1): 1-6, 2014 (June)

APA, Harvard, Vancouver, ISO, and other styles

11

Grunder, Gabriela, Yvonne Zysset-Aschmann, Florence Vollenweider, Thomas Maier, Stephan Krähenbühl, and Juergen Drewe. "Lack of Pharmacokinetic Interaction between Linezolid and Antacid in Healthy Volunteers." Antimicrobial Agents and Chemotherapy 50, no. 1 (January 2006): 68–72. http://dx.doi.org/10.1128/aac.50.1.68-72.2006.

Full text

Abstract:

ABSTRACT Several antibiotics show significant pharmacokinetic interactions when they are given orally concomitantly with antacids. The objective of this study was to evaluate the effects of antacid (containing magnesium) on the pharmacokinetics of linezolid. A single dose of 600 mg linezolid was given orally alone and 10 min after administration of the antacid Maalox 70mVal, which contains 600 mg magnesium hydroxide and 900 mg aluminum hydroxide, to nine healthy males and nine healthy females in a crossover and randomized study. Linezolid plasma concentrations were determined by high-performance liquid chromatography, and pharmacokinetic parameters were calculated for both treatments. Coadministration with antacids did not change the pharmacokinetics of linezolid. The ratios (90% confidence intervals) of the individual values of the area under the concentration-time curve and the maximum concentration in plasma (C max) (linezolid plus antacid versus linezolid alone) were 1.01 (0.99 to 1.02) and 0.99 (0.96 to 1.02), respectively. Likewise, no significant difference in any of the other pharmacokinetic parameters was observed between the treatment groups (the time to C max, lag time, volume of distribution [V/F], and clearance [CL/F]). However, a significant sex difference was observed for AUC, C max, V/F, and CL/F; and these differences could be almost completely explained by the differences in body weight between males and females. No clinically relevant adverse effects were detected under either condition. The coadministration of antacids had no effect on the pharmacokinetics of linezolid. This demonstrates that the oral absorption of linezolid was not affected by the presence of antacids containing magnesium hydroxide and aluminum hydroxide. Antacids can be safely administered together with linezolid.

APA, Harvard, Vancouver, ISO, and other styles

12

Dhawal, Pranjali P., and Siddhivinayak S. Barve. "Preliminary in-vitro evaluation of marketed formulations for antacid activity." International Journal of Basic & Clinical Pharmacology 9, no. 1 (December 24, 2019): 57. http://dx.doi.org/10.18203/2319-2003.ijbcp20195764.

Full text

Abstract:

Background: Hydrochloric acid (pH 1.5-3.5) being the major component of gastric acid is produced by parietal cells of stomach. Its secretion is a complex and relatively energetically expensive process. The preservation of acidity of stomach is evidently important because of its implications in peptic and duodenal ulceration.Methods: In the present study, we attempted to compare the activity of 13 (F1-F13) antacid formulations (5-liquid, 4- quick releases and 4- tablets) by using acid-base neutralization studies. Preliminary antacid test (PAT) was performed to define whether the given formulation falls under the category of antacid wherein the pH of the antacid-acid (HCl) solution should be higher than pH of 3.5. The chosen antacids were further subjected to acid neutralizing capacity (ANC) (reaction between the sample of antacid and amount of acid neutralized by the formulation) and acid neutralizing potential (ANP) which explains the time duration during which a given sample of antacid can maintain pH above 3.5).Results: Out of the 13 samples tested, two formulations of pastels (F6, F12) were rejected as per the standard protocol of classifying formulations as antacids after screening for PAT. Sample F5 was found to have the highest ANC. F7 also showed highest ANC among the tablets tested. Also, F13 showed better ANC and ANP as in comparison to other quick releases.Conclusions: Digene products (F5, F7, and F13) showed better antacid properties. This data would provide insights into development of drug, comparison between antacids depending on their chemical formulation and determination of dosage to avoid plausible side effects.

APA, Harvard, Vancouver, ISO, and other styles

13

Tsou, V. Marc, Rose M. Young, Michael H. Hart, and Jon A. Vanderhoof. "Elevated Plasma Aluminum Levels in Normal Infants Receiving Antacids Containing Aluminum." Pediatrics 87, no. 2 (February 1, 1991): 148–51. http://dx.doi.org/10.1542/peds.87.2.148.

Full text

Abstract:

Aluminum toxicity is a documented cause of encephalopathy, anemia, and osteomalacia. Excretion is primarily renal; therefore, patients with renal insufficiency are at risk for aluminum accumulation and toxicity. This has been demonstrated in uremic children treated with aluminum-containing antacids. The purpose of this study was to determine whether plasma aluminum levels were elevated in infants with normal renal function during prolonged aluminum-containing antacid use. Ten study infants (mean age = 5.8 months), who had been receiving antacids for at least 1 week, were compared with 16 control infants (mean age = 9.8 months) not receiving antacids. The study patients consumed 123 ± 16 mg/kg per day (mean ± SEM) of elemental aluminum for an average of 4.7 weeks. Their plasma aluminum level (37.2 ± 7.13 µg/L) was significantly greater than that of the control group (4.13 ± 0.66 µg/L) (P < .005). It is concluded that plasma aluminum levels may become elevated in infants with normal renal function who are consuming high doses of aluminum-containing antacids. The safety of antacids containing aluminum should not be assumed and they should be used judiciously in infants, with careful monitoring of the aluminum dose and plasma level.

APA, Harvard, Vancouver, ISO, and other styles

14

Savla, Hemali M., Isha V. Naik, Chandrashekhar Gargote, Nischal Shashidhar, Sneha Nair, and Mala D. Menon. "Physicochemical properties of various alginate-based raft-forming antacid products: a comparative study." International Journal of Basic & Clinical Pharmacology 10, no. 12 (November 22, 2021): 1330. http://dx.doi.org/10.18203/2319-2003.ijbcp20214449.

Full text

Abstract:

Background: Alginate-based, raft-forming antacid products with reflux suppressant activity are complex formulations expected to achieve effective raft formation and cause elimination or displacement of the acid pocket, which is typically manifested in gastroesophageal reflux disease (GERD).Methods: In the present study, six alginate-based raft-forming products commercially available in the Indian market were compared in terms of their acid neutralization properties, strength, resilience and structural and thermal properties of their rafts. Percent alginate content was also determined.Results: Rafts of products containing calcium-based antacids formed voluminous, porous and floating rafts within seconds of addition to the simulated gastric fluid (SGF) compared with the products that contained aluminium and magnesium-based antacids. Marked differences were not evident in the ANC (acid neutralization capacity) values of the various products. No correlation was observed between ANC and raft-forming capacity or duration of neutralization. Raft structures affected their neutralization profiles. Rafts of porous and absorbent nature could retain their ANC probably due to release of trapped antacids. Further, raft strengths of only two products were above the British Pharmacopoeia specification of not less than 7.5 g. Sodium alginate content was within specifications (85-115%) for three of the six products.Conclusions: Raft-forming formulations with higher alginate content and calcium-based antacids have better physicochemical properties such as ANC, neutralization profiles, raft strength and raft resilience than those with lower alginate content or those containing aluminium or magnesium-based antacids.

APA, Harvard, Vancouver, ISO, and other styles

15

Uzunović, Alija, and Edina Vranić. "Influence of Type and Neutralisation Capacity of Antacids on Dissolution Rate of Ciprofloxacin and Moxifloxacin from Tablets." Bosnian Journal of Basic Medical Sciences 9, no. 1 (February 20, 2009): 89–93. http://dx.doi.org/10.17305/bjbms.2009.2864.

Full text

Abstract:

Dissolution rate of two fluoroquinolone antibiotics (ciprofloxacin and moxifloxacin) was analysed in presence/absence of three antacid formulations. Disintegration time and neutralisation capacity of antacid tablets were also checked. Variation in disintegration time indicated the importance of this parameter, and allowed evaluation of the influence of postponed antacid-fluoroquinolone contact. The results obtained in this study showed decreased dissolution rate of fluoroquinolone antibiotics from tablets in simultaneous presence of antacids, regardless of their type and neutralisation capacity.

APA, Harvard, Vancouver, ISO, and other styles

16

D'arcy, P. F., and James C. Mcelnay. "Drug-Antacid Interactions: Assessment of Clinical Importance." Drug Intelligence & Clinical Pharmacy 21, no. 7-8 (July 1987): 607–17. http://dx.doi.org/10.1177/1060028087021007-806.

Full text

Abstract:

Antacids and adsorbents are commonly used preparations that are generally considered to be pharmacologically inert and free from adverse effects. They may, however, interact with a diverse range of primary drugs and the sequelae can be disadvantageous to the efficacy of the primary medication. Many such reports in the literature are based on animal experiments, or on single-dose studies in healthy subjects. Some reports are anecdotal and are unconfirmed; others are based solely on in vitro evidence. Potentially important interactions have been suggested for a relatively small group of drugs: tetracyclines, phenytoin, digoxin, chloroquine, cimetidine, quinidine, nonsteroidal antiinflammatory drugs, and beta-blocking agents. The evidence for these has been critically evaluated, as well as for antacid-anticoagulant and antacid-nitrofurantoin interactions that have been wrongly emphasized in the literature. The majority of literature reports on interactions with antacids have been overemphasized; only ferrous sulfate-, isoniazid-, and tetracycline-antacid interactions fall into a category I importance (scale I–III of descending importance). This category is for those interactions with good evidence of actual or potential importance in patients or in relevant studies on normal subjects.

APA, Harvard, Vancouver, ISO, and other styles

17

Mostoufi, Azar, Neda Bavarsad, Sahar Aryanfar, and Abbas Akhgari. "New Natural Marine Antacid Drug from Cuttlebone." Pharmaceutical Sciences 24, no. 3 (September 23, 2018): 227–34. http://dx.doi.org/10.15171/ps.2018.33.

Full text

Abstract:

Background: Antacids are the most commonly used medications for fast symptomatic relief of gastric disorders. Because of adverse effects, low efficiency and the high cost of some chemical antacids, identifying a natural medicine with high efficiency and low cost seems useful. Therefore, the aim of the present study was to prepare antacid tablets from Cuttlefish bone and assessment of its antacid properties. Methods: 24 different formulations of cuttlefish bone were prepared by direct compression using different fillers (starch, cellulose, lactose, and mixture of those) in different ratios of the drug. Characterization of powders and tablets was done on all formulations and marketed dosage forms (calcium carbonate and Al-Mg). Results: Weight uniformity, hardness, and friability of all formulations were in acceptable range. Tablets prepared by calcined cuttlebone disintegrated in longer time due to their higher hardness which were mostly higher than 5 Kg. Also, disintegration time of formulations 50-50 (lower dose of cuttlebone) was less than other tablets (2 minutes or less). Results of antacid capacity showed that formulations 90-10 and 80-20 raise the acidic pH of the medium above 7.5, which were the same as or more than the capacity of the marketed tablets.

APA, Harvard, Vancouver, ISO, and other styles

18

Trukhan, D. I., E. N. Degovtsov, and A. Yu Novikov. "Antacids in real clinical practice." Meditsinskiy sovet = Medical Council, no. 8 (May 19, 2023): 59–67. http://dx.doi.org/10.21518/ms2023-141.

Full text

Abstract:

Currently, proton pump inhibitors (PPIs), H2-histamine receptor blockers (H2-blockers), antacids, and anticholinergics are used to treat acid-dependent diseases of the gastrointestinal tract. PPIs are considered the most effective drugs for the treatment of acid-dependent diseases of the gastrointestinal tract. However, in real clinical practice, interest remains in the use of antacids in acid-dependent diseases. This is due to the fact that antacids not only adsorb hydrochloric acid in the gastric lumen (by buffering the HCl present in the stomach, without a significant effect on its production) and reduce the proteolytic activity of gastric juice (reducing/ neutralizing the activity of pepsin), but also have a number of other pharmacotherapeutic properties demanded by the gastroenterological patient. Antacids in addition to antisecretory action have: 1) cytoprotective, primarily gastroprotective, action, which is mediated by: a) stimulation of the synthesis of bicarbonates and prostaglandins; b) mucoprotection – an increase in the production of protective mucus by epithelial cells; c) switching of the epithelial growth factor and its concentration in the area of erosive and ulcerative defects, which in turn activates angiogenesis, cell proliferation and local reparative and regenerative processes; 2) enveloping and adsorbing action, through chelation of lysolecithin and bile acids, which have an aggressive damaging effect on the upper gastrointestinal tract; 3) regulate gastroduodenal motility due to: a) antispasmodic action and streamlining gastroduodenal evacuation; b) decrease in intracavitary pressure in the stomach and duodenum; b) obstacles to the formation of duodenogastric reflux. To date, combined preparations, the basic composition of which includes magnesium hydroxide and aluminum hydroxide, meet the basic requirements for non-absorbable antacids. In conclusion, the authors present a number of clinical situations, indicating that today rationally prescribed antacid drugs successfully and significantly solve the main tasks of symptomatic therapy of acid-dependent and other diseases of the gastrointestinal tract, significantly improving the quality of life of patients.

APA, Harvard, Vancouver, ISO, and other styles

19

Ogilvie, A. L., and Michael Atkinson. "Does Dimethicone Increase the Efficacy of Antacids in the Treatment of Reflux Oesophagitis?" Journal of the Royal Society of Medicine 79, no. 10 (October 1986): 584–87. http://dx.doi.org/10.1177/014107688607901009.

Full text

Abstract:

Dimethicone is a common additive to antacids, although its value in the treatment of reflux oesophagitis is unproven. Its efficacy was assessed by comparing the effect of a dimethicone-containing antacid gel (Asilone Gel) with a simple antacid gel in a double-blind trial in 45 patients with reflux oesophagitis. Thirty-eight patients completed the eight-week course of therapy. Antacid therapy alone resulted in a significant improvement of both symptoms and oesophagitis in gastro-oesophageal reflux. The inclusion of dimethicone in the antacid gel preparation did not confer any benefit in terms of symptomatic assessment but did confer a small advantage with regard to objective markers of oesophageal inflammation, suggesting that a dimethicone-containing antacid is of value in the treatment of symptomatic gastro-oesophageal reflux.

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Antacids." Reactions Weekly &NA;, no. 544 (April 1995): 4. http://dx.doi.org/10.2165/00128415-199505440-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ching, Chi-Kong, and Shiu-Kum Lam. "Antacids." Drugs 47, no. 2 (February 1994): 305–17. http://dx.doi.org/10.2165/00003495-199447020-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Antacids." Reactions Weekly &NA;, no. 629 (November 1996): 6. http://dx.doi.org/10.2165/00128415-199606290-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Antacids." Reactions Weekly &NA;, no. 865 (August 2001): 6–7. http://dx.doi.org/10.2165/00128415-200108650-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Antacids." Reactions Weekly &NA;, no. 878 (November 2001): 6. http://dx.doi.org/10.2165/00128415-200108780-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Antacids." Reactions Weekly &NA;, no. 1229 (November 2008): 4–5. http://dx.doi.org/10.2165/00128415-200812290-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Antacids." Reactions Weekly &NA;, no. 286 (February 1990): 4. http://dx.doi.org/10.2165/00128415-199002860-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Antacids." Reactions Weekly &NA;, no. 342 (March 1991): 4. http://dx.doi.org/10.2165/00128415-199103420-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Antacids." Reactions Weekly &NA;, no. 482 (December 1993): 6. http://dx.doi.org/10.2165/00128415-199304820-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

BRAND, JOSEPH M., and FRANK R. GREER. "Hypermagnesemia and Intestinal Perforation Following Antacid Administration in a Premature Infant." Pediatrics 85, no. 1 (January 1, 1990): 121–24. http://dx.doi.org/10.1542/peds.85.1.121.

Full text

Abstract:

Antacid therapy is widely used prophylactically in pediatric intensive care units to prevent stress ulcers. It has also been used in the medical management of gastric bleeding in newborn infants.1,2 Complications of antacid therapy in the newborn infant have included hypotonia, asymptomatic hypermagnesemia without hypocalcemia, as well as aluminum-hydroxide bezoar formation.1-3 This is the first report in which a severe degree of these complications of magnesium-containing antacids is described that includes hypermagnesemia with hypocalcemia and in which a strong case is made against the use of antacid therapy in the treatment of gastric bleeding in very low birth weight infants.

APA, Harvard, Vancouver, ISO, and other styles

30

Auclair, Barbara, David E. Nix, Rodney D. Adam, Gordon T. James, and Charles A. Peloquin. "Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids." Antimicrobial Agents and Chemotherapy 45, no. 3 (March 1, 2001): 810–14. http://dx.doi.org/10.1128/aac.45.3.810-814.2001.

Full text

Abstract:

ABSTRACT This study was conducted in order to (i) determine the effect of food, orange juice, or antacids on the absorption of a single oral 500-mg dose of ethionamide (ETA) in healthy volunteers, including an assessment of bioequivalence, and (ii) determine ETA population pharmacokinetic (PK) parameters. The pharmacokinetics of ETA in serum was determined for 12 healthy males and females in a randomized, four-period crossover study. Volunteers received single 500-mg doses of ETA either on an empty stomach (reference) or with food, orange juice, or antacids. Serum samples were collected for 48 h and assayed by high-performance liquid chromatography. Data were analyzed by noncompartmental and population methods. Mean test/reference ratios and 90% confidence intervals were determined. No statistically significant differences were seen in the maximum concentration of ETA (C max), time to maximum concentration (T max), or area under the concentration-time curve from 0 h to infinity (AUC0–∞) between the four treatments (P > 0.05 by analysis of variance). The least-squares mean ratios (with confidence intervals in parentheses) for C maxwere 105% (81.2 to 135%) after orange juice, 94% (72.8 to 121%) after food, and 88% (68.4 to 114%) after antacids. The least-squares mean ratios (with confidence intervals is in parentheses) for AUC0–∞ were 91% (72.7 to 115%) after orange juice, 96% (76.4 to 121%) after food, and 95% (75.5 to 120%) after antacids. The mean T max was slightly prolonged following antacid or food administration (2.3 to 2.6 h) compared to administration on an empty stomach or with juice (1.7 to 1.9 h). The median population PK parameters were as follows:K a = 0.37 to 0.48 h−1,V/F = 2.0 to 2.8 liters/kg, CL/F = 56.5 to 72.2 liters/h, and terminal half-life = 1.7 to 2.1 h, where Ka is the absorption rate constant,V is the volume of distribution, and CL is clearance. The PK behavior of ETA was not significantly modified by the different conditions studied. Mean ratios for AUC ranged from 0.91 to 0.96 for the orange juice, food, and antacid treatments, indicating a minimal effect on relative bioavailability. ETA can, therefore, be administered with food if tolerance is an issue.

APA, Harvard, Vancouver, ISO, and other styles

31

Yulian, Agung, Beta Ria Yunita, Desti Nadia, Fadhila Nur Afifah, Faiha Putri Kanza, Febby Trianingsih, and Gerend Erlina Ayu Putri. "Analysis of antacid tablets using the alkalimetric titration method." Asian Journal of Analytical Chemistry 1, no. 1 (June 8, 2023): 25–31. http://dx.doi.org/10.53866/ajac.v1i1.284.

Full text

Abstract:

Titrimetry is a quantitative analysis concerned with measuring the volume of a solution of known concentration required to react with the substance to be determined. On the other hand, alkalimetry determines the levels of acidic compounds that are reacted with essential standard solutions. Antacids can treat stomach disorders resulting from excess stomach acid production. The active ingredient is a mixture of magnesium hydroxide and aluminum hydroxide which is a weak base that reacts with acids. This study aims to determine whether the levels of antacid tablets in several pharmacies in Bandar Lampung City by looking at the expiration date meet USP30_NF25 requirements, namely between 90.0% -110% of the amount stated on the label. The method used is alkalimetry with a back titration technique, in which excess acid is added to the sample to react with antacids, and the excess acid is titrated using sodium hydroxide with phenolphthalein solution as an indicator.

APA, Harvard, Vancouver, ISO, and other styles

32

Uryu, Kiyoaki, Yoshinori Imamura, Rai Shimoyama, Maki Hayashi, Megu Ohtaki, Keiko Otani, Hiromasa Harada, and Hironobu Minami. "Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids." JCO Oncology Practice 19, no. 11_suppl (November 2023): 530. http://dx.doi.org/10.1200/op.2023.19.11_suppl.530.

Full text

Abstract:

530 Background: The introduction of new-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has afforded promising overall survival (OS) outcomes in clinical trials for non-small cell lung cancer (NSCLC). However, given the high cost associated with these agents, the extent of their adoption and the resulting impact on OS in real-world clinical settings remains uncertain. Concomitant use of antacids reportedly decreases the absorption of first-generation EGFR-TKIs, accompanied by a reduction in OS. Although concomitant antacids do not reduce the absorption of second- and third-generation EGFR-TKIs, the impact on OS remains unexplored. Methods: We conducted a nationwide retrospective cohort study utilizing data from the Tokushukai Real-world Data project and reviewed clinical data of consecutive patients with NSCLC who were treated with EGFR-TKIs between April 2010 and March 2020. Cox regression analyses were performed to examine the associations between OS and patient/tumor-related factors, hospital volume, hospital type, study period, and first-line EGFR-TKIs. Furthermore, we examined differences in OS between patients treated with and without concomitant antacids. Results: A total of 758 patients (58.5% females; median age, 73 years) were included. Over the study period, we noted increased utilization of osimertinib as the first-line EGFR-TKI. With a median follow up of 15.8 months, median OS was 28.4 months (95% confidence interval, 15.3–31.0). Age, body mass index, disease status, EGFR mutational status, and first-line EGFR-TKI were identified as significant prognostic factors. The 2-year OS rates for gefitinib, erlotinib, afatinib, and osimertinib were 70.1, 67.8, 75.6, and 90.8%, respectively. Low-volume hospitals showed a treatment transition to osimertinib over time and were non-inferior to high-volume hospitals in terms of the OS achieved. Patients administering gefitinib, erlotinib, afatinib, and osimertinib with concomitant antacids had lower OS values than those not taking concomitant antacids, with hazard ratios of 1.742, 1.329, 1.729, and 5.040, respectively. Conclusions: Our real-world data revealed that new-generation EGFR-TKIs could afford a prolonged OS irrespective of the volume and type of the hospital. Surprisingly, the concomitant antacid use was associated with poor OS in patients treated with osimertinib.

APA, Harvard, Vancouver, ISO, and other styles

33

Aghayere, G. E., H. A. Okeri, and H. O. Abanum. "Comparative Assessment of the Acid-Neutralizing Capacity, Price and selected Physical Properties of different Antacids Suspensions available in Benin City, Edo State, Nigeria." Journal of Basic and Social Pharmacy Research 2, no. 4 (2022): 11–21. http://dx.doi.org/10.52968/27451777.

Full text

Abstract:

Background: Patients are often faced with the challenge of choosing an antacids suspension that will provide effective and prompt relief from excessive gastric acid secretion. Objective: The aim was to evaluate acid-neutralizing capacity (ANC), price and selected physical properties of twenty (20) brands of antacids suspensions from pharmacies in Benin metropolis, Nigeria. Materials and Methods: United States Pharmacopeia assay method was used to determine the ANC. Visual inspection, pH, relative density and flow times were determined using standard methods. Results: The ANC of all the brands of antacids suspensions was above the US FDA requirement for effective antacids (≥5 mEq per dose). Brand E had the highest ANC of 27.15 mEq/ 10 mL while brand C had the lowest at 11.60 mEq/ 10 mL. All the antacids suspensions had pH range between 7.30 and 8.76. The flow time was found to be highest with sample N (70.11 ± 0.35) min and lowest with sample A (0.27 ± 0.01) min. The relative density was highest with sample N (1.28 ± 0.02) and lowest with sample B (1.03 ± 0.00). There was no significant difference in ANC values between imported and locally manufactured antacids suspensions. However, there was significant difference in their prices. Conclusion: Rapid and effective acid-neutralizing capacity of antacids is achieved with antacids suspensions containing at least two active pharmaceutical ingredients. Most of the antacids contain aluminium hydroxide and magnesium hydroxide. When medication is needed for symptomatic relief from acid reflux disorders, antacids containing these active ingredients will be effective.

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Antacids interaction." Reactions Weekly &NA;, no. 443 (March 1993): 5. http://dx.doi.org/10.2165/00128415-199304430-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Antacids/sucralfate." Reactions Weekly &NA;, no. 446 (April 1993): 5. http://dx.doi.org/10.2165/00128415-199304460-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Maton, Paul N., and Michael E. Burton. "Antacids Revisited." Drugs 57, no. 6 (1999): 855–70. http://dx.doi.org/10.2165/00003495-199957060-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Antacids abuse." Reactions Weekly &NA;, no. 341 (March 1991): 3. http://dx.doi.org/10.2165/00128415-199103410-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Musfiroh, Ida, Aliya Nur Hasanah, Gia A. Faradiba, Ida Ayumiati, Mutakin Mutakin, and Muchtaridi Muchtaridi. "Modification of Extraction Methods on Determining Simeticone Suspension Using FTIR Method." Indonesian Journal of Pharmaceutical Science and Technology 6, no. 3 (October 19, 2019): 125. http://dx.doi.org/10.24198/ijpst.v6i3.22355.

Full text

Abstract:

Antacids dosage form are a class of drugs used to chemically bind and neutralize stomach acid. Simethicone is one of the antacids that works as an antiflatulant. In an effort to guarantee the quality of a preparation, a valid analysis method is needed that meets the validation parameters. This study aims to modified of extraction method of the simethicone content of suspension samples using the FTIR method. The methods include simethicone modification of extraction from suspension preparations with toluene solvents and hydrochloric acid (2:5) 3.35. Validation methods include: determination of precision, accuracy, limit of detection (LOD), and limit of quantification (LOQ) at wave number 1261 cm-1 and determination of the content of samples of simethicone suspension. The results showed that linearity parameters with a correlation coefficient of 0.997 in a concentration range of 1000-10,000 ppm, precision with a value of KV <2%, LOD and LOQ, respectively 378.97 and 1250.59 ppm. The results of the determination of simethicone suspension samples indicate that this method met the requirements of the validation parameters.Keywords: Validation, Simethicone, Infrared Spectrophotometry, antacid

APA, Harvard, Vancouver, ISO, and other styles

39

Nakamura, Takeaki, Ryosuke Watanabe, Takahiro Yamamura, Kazuaki Harada, Yasuyuki Kawamoto, Satoshi Yuki, Naoya Sakamoto, and Yoshito Komatsu. "Retrospective analysis of drug intake affecting the intestinal microbiota and the therapeutic effects of chemotherapy on gastric cancer." Journal of Clinical Oncology 41, no. 4_suppl (February 1, 2023): 379. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.379.

Full text

Abstract:

379 Background: Administration of some medications, such as antibiotics, antacids, and probiotic supplementation, may affects the treatment outcomes of immune checkpoint inhibitors (ICIs), through the change of gut microbiota in cancer patients. Even when ICIs are combined with cytotoxic chemotherapy (Chemo), a use of such medications is expected to be a potential biomarker. However, the impacts of medications that affect gut microbiota on the efficacy of Chemo alone is unclear. Methods: We retrospectively analyzed patients who received fluoropyrimidines and platinum-based therapy for advanced gastric cancer in our institutions between January 2010 and December 2019. Progression-free survival (PFS) and overall survival (OS) by history of antibiotic/antacid/probiotic supplementation, were analysed. Results: A total of 101 pts were analyzed. Median age was 66 years (range, 30-81), female/male; 36/65, 1st-line regimen SP/XP/SOX/XELOX/FOLFOX; 52/2/39/1/7. In all patients, The median PFS for first-line treatment was 5.8 months (95% CI: 5.0-7.3) and the median OS was 15.5 months (95% CI: 12.5-18.6).Univariate analysis for PFS of first-line treatment did not show a significant difference in antibiotic use (median 7.6 vs 5.5 months, HR: 0.79 [95%CI: 0.50-1.24], p=0.31), oral antacids (median 6.6 vs 5.8 months, HR: 0.96 [95%CI: 0.61-1.54], p=0.89) and probiotic supplementation (median 9.1 vs 5.5 months, HR: 0.7 [95%CI: 0.38-1.26], p=0.24). Similarly in OS, the use of antibiotics (median 18.4 versus 13.4 months, HR: 0.85 [95%CI: 0.53-1.37], p=0.49), oral antacids (median 16.3 vs 13.8 months, HR: 1.15 [95%CI: 0.70-1.88], p=0.58), and oral probiotic supplementation (median 20.2 vs 13.8 months, HR: 0.77 [95%CI: 0.42-1.40], p=0.40), with no statistically significant differences. Conclusions: In this study, there were no significant differences in PFS and OS between patients administered with or without antibiotics, antacids, or probiotic supplementation. Future studies are expected to investigate the impacts of these medications on the treatment outcomes of ICIs+Chemo combination.

APA, Harvard, Vancouver, ISO, and other styles

40

Surdea-Blaga, Teodora, Ion Băncilă, Daniela Dobru, Vasile Drug, Ovidiu Frățilă, Adrian Goldiș, Simona M. Grad, et al. "Mucosal Protective Compounds in the Treatment of Gastroesophageal Reflux Disease. A Position Paper Based on Evidence of the Romanian Society of Neurogastroenterology." Journal of Gastrointestinal and Liver Diseases 25, no. 4 (December 1, 2016): 537–46. http://dx.doi.org/10.15403/jgld.2014.1121.254.dea.

Full text

Abstract:

Background & Aims: Gastroesophageal reflux disease (GERD) therapy is challenging and suppression of acid secretion or prokinetics do not cure all cases. Some drugs with protective action on the esophageal mucosa have been used alternatively or in association with proton pump inhibitors (PPIs) and/or prokinetics. The Romanian Society of Neurogastroenterology undertook an Evidence-Based analysis, from which this position paper evolved. Methods: We performed a systematic literature search in PubMed until October 2015, using the terms: sucralfate, guaiazulene, gaiazulene, dimethicone, alginate, antacids and gastroesophageal reflux. Forty-seven papers were included and analyzed. Several statements were elaborated regarding the use of these drugs in GERD. The evidence and recommendations were discussed between the authors. Results: There is evidence in the medical literature suggesting the benefit of these drugs in GERD. In patients with persistent or mild reflux symptoms antacids rapidly relieve heartburn. Alginate-antacid combination is superior both over placebo and antacids to treat mild reflux symptoms, and can be used to treat persistent reflux symptoms despite acid suppressant therapy. Sucralfate is superior over placebo in alleviating GERD symptoms and can be used as maintenance therapy. Guaiazulene-dimethicone improves the quality of life in patients with GERD. Conclusions: Drugs used to protect the esophageal mucosa against acid are useful in alleviating chronic heartburn, especially in patients with mild reflux symptoms. Abbreviations: CS: Chondroitin sulfate; DA: Double Action; EE : Erosive esophagitis ; GERD: Gastroesophageal reflux disease; HA: Hyaluronic acid; H2RA: Histamine 2 receptor antagonist; ITT: Intention to treat; IM: Irsogladine maleate; NERD: Non-erosive reflux disease; PPIs: Proton pump inhibitors; RCT: Randomized controlled trial; RDQ: Reflux disease questionnaire; QoL: Quality of life.

APA, Harvard, Vancouver, ISO, and other styles

41

Peloquin, Charles A., Amy E. Bulpitt, George S. Jaresko, Roger W. Jelliffe, Gordon T. James, and David E. Nix. "Pharmacokinetics of Pyrazinamide under Fasting Conditions, with Food, and with Antacids." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18, no. 6 (November 12, 1998): 1205–11. http://dx.doi.org/10.1002/j.1875-9114.1998.tb03138.x.

Full text

Abstract:

Study Objectives. To determine intrasubject and intersubject variability in, and the effects of food and antacids on, the pharmacokinetics of pyrazinamide (PZA).Design. Randomized, four‐period, crossover phase I study.Subjects. Fourteen healthy men and women volunteers.Interventions. Subjects ingested single doses of PZA 30 mg/kg under fasting conditions twice, without a high‐fat meal and with an aluminum‐magnesium antacid. They also received standard dosages of isoniazid, rifampin, and ethambutol.Measurements and Main Results. Serum was collected for 48 hours and assayed by gas chromatography with mass selective detector. Data were analyzed by noncompartmental methods and a compartmental analysis using nonparametric expectation maximization. Both fasting conditions produced similar results: mean PZA Cmax 53.4 ± 10.4 μg/ml, Tmax 1.43 ± 1.06 hours, and AUC0‐∞, 673 ± 79.7 μg·hr/ml. Fasting results are similar to those in previous reports. In the presence of antacids, subjects had a mean Cmax of 55.6 ± 9.0 μg/ml, Tmax of 1.43 ± 1.23 hours, and AUC0‐∞ of 628 ± 88.4 μg·hr/ml. In the presence of the high‐fat meal, mean Cmax was 45.6 ± 9.44 μg/ml, Tmax 3.09 ± 1.74 hours, and AUC0‐∞ 687 ± 116 μg·hr/ml.Conclusions. These small changes in Cmax. Tmax, and AUC0‐∞. can be avoided by giving PZA on an empty stomach whenever possible.Conclusion: Serum concentrations in this study were consistent with those described previously. In addition, PZA's kinetic behavior was consistent between fasting treatments. Antacids and food had minimal effects on the agent's absorption. Samples drawn between 0.5 and 3 hours after dosing approached Cmax for most subjects, with 1 hour being closest. Samples drawn as early as day 2 of daily PZA therapy will produce serum concentrations that approach steady‐state values.

APA, Harvard, Vancouver, ISO, and other styles

42

JACOBS, M. G., P. R. CROCKER, W. G. BOWSHER, and H. N. WHITFIELD. "Beware of Antacids!" British Journal of Urology 66, no. 6 (December 1990): 661. http://dx.doi.org/10.1111/j.1464-410x.1990.tb07207.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Antacids treat hypercholesterolaemia." Inpharma Weekly &NA;, no. 821 (January 1992): 9. http://dx.doi.org/10.2165/00128413-199208210-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Preheim, L. C., T. A. Cuevas, J. S. Roccaforte, M. A. Mellencamp, and M. J. Bittner. "CIPROFLOXACIN AND ANTACIDS." Lancet 328, no. 8497 (July 1986): 48. http://dx.doi.org/10.1016/s0140-6736(86)92596-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Fleming, LauraW, T. A. Moreland, W. K. Stewart, and A. C. Scott. "CIPROFLOXACIN AND ANTACIDS." Lancet 328, no. 8501 (August 1986): 294. http://dx.doi.org/10.1016/s0140-6736(86)92120-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

MAESEN, F. P. V., B. I. DAVIES, W. H. GERAEDTS, and C. A. SUMAJOW. "Ofloxacin and antacids." Journal of Antimicrobial Chemotherapy 19, no. 6 (1987): 848–50. http://dx.doi.org/10.1093/jac/19.6.848.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Hollander, D., and A. Tarnawski. "Are antacids cytoprotective?" Gut 30, no. 2 (February 1, 1989): 145–47. http://dx.doi.org/10.1136/gut.30.2.145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Shetty, Bhuvan, and Mrinal Kumar Vishwanath. "An expert opinion on antacids: A review of its pharmacological properties and therapeutic efficacy." F1000Research 11 (September 15, 2022): 1057. http://dx.doi.org/10.12688/f1000research.124024.1.

Full text

Abstract:

Acidity caused by common gastric conditions such as non-ulcer dyspepsia, duodenal ulcer, gastric ulcer, stress gastritis, gastroesophageal reflux disease (GERD), pancreatic insufficiency, bile acid-mediated diarrhea, biliary reflux, and constipation can be treated by administration of potent and efficacious acid suppressant (anti-secretory) agents such as antacids, histamine H2 receptor blockers, and proton pump inhibitors (PPIs). Antacids provide symptomatic relief from hyperacidity as well as other associated conditions by neutralizing the gastric acid directly, thereby raising the gastric pH, attenuating the pepsin activity, restoring acid-base balance, and increasing prostaglandin and bicarbonate secretion. The effectiveness of antacids is determined by its acid neutralizing capacity (ANC) and buffering capacity. Antacids containing a combination of aluminum hydroxide, magnesium hydroxide, and other ingredients such as those present in Digene showed better therapeutic efficacy even at low dosage with fewer side effects, persistent increase in gastric pH, faster and longer duration of pain relief, and fast relief from gas. Various clinical studies suggest that to obtain fast symptomatic relief, the treating physician can utilize antacids with the highest neutralizing capacities like Digene.

APA, Harvard, Vancouver, ISO, and other styles

49

Hailstone, Emily, Sheryl Falkos, Rosa Vidal, K. Ashley Jones, Philippe R. Gaillard, Shirley Fan, and Allison M. Chung. "Impact of Acid Suppression Therapy on Iron Supplementation in the Pediatric Intensive Care Unit." Journal of Pediatric Pharmacology and Therapeutics 26, no. 4 (May 1, 2021): 366–71. http://dx.doi.org/10.5863/1551-6776-26.4.366.

Full text

Abstract:

OBJECTIVE We assessed the impact of acid suppression therapy (i.e., ranitidine or proton pump inhibitors) on iron supplementation and its ability to maintain or alter laboratory values that are commonly associated with anemia. METHODS This was a prospective, observational trial. The primary outcome was changes in serum iron levels from baseline. Secondary outcomes were changes in hemoglobin (Hgb) and hematocrit (Hct), transfusions, and maintenance of an alkalotic gastric pH. RESULTS Thirty-four patients (mean 24 ± 43 months) met inclusion criteria. The serum iron levels increased to 50.9 ± 24.6 mcg/dL by day 3. The mean difference from baseline was 1.5 mcg/dL (95% CI, 1.14–1.98, p = 0.0056). Gastric pH increased to 4.68 ± 1.49 on day 5. The mean Hgb and Hct increased on day 5 to 10 ± 1.06 g/dL and 29.6% ± 3.27%, respectively. The mean difference of Hgb was 1.15 g/dL (95% CI, 0.51–1.78, p = 0.0009). The mean difference of Hct was 3.04% (95% CI, 1.11–4.97, p = 0.0032). CONCLUSIONS The use of antacids along with oral ferrous sulfate supplementation did not affect the absorption of iron. Serum iron, Hgb, and Hct all showed statistically significant increases despite combined antacid and iron therapy. Thus, despite use of antacids, combination use showed increases in iron absorption.

APA, Harvard, Vancouver, ISO, and other styles

50

Колбай, М. Г., К. С. Жакипбеков, and Н. А. Рахимбаев. "REVIEW OF ANTACID PREPARATIONS IN THE MODERN TREATMENT OF ACID-DEPENDENT DISEASES REGISTERED IN THE REPUBLIC OF KAZAKHSTAN." Farmaciâ Kazahstana, no. 1 (May 19, 2022): 73–81. http://dx.doi.org/10.53511/pharmkaz.2022.55.97.012.

Full text

Abstract:

Современные антациды не только обладают способностью связывать соляную кислоту, но и обладают выраженным цитопротекторным действием, что существенно отличает их от блокаторов желудочной секреции и дает основание рассматривать данную группу лекарственных средств как лекарственный препарат, обладающий комбинированным действием на патогенетические механизмы эрозивного и язвенного поражения слизистой оболочки верхних отделов желудочнокишечного тракта. Целью нашей статьи является анализ значимости антацидных препаратов на рынке РК. В данной статье мы ответим на вопросы о том, почему антациды продолжают широко использоваться в повседневной практике, какие новые свойства были выявлены в этих препаратах, что позволило расширить диапазон показателей Modern antacids not only have the ability to bind hydrochloric acid, but also have a pronounced cytoprotective effect, which signi cantly distinguishes them from gastric secretion blockers and gives grounds to consider this group of drugs as a drug that has a combined effect on the pathogenetic mechanisms of erosive and ulcerative lesions of the mucous membrane of the upper gastrointestinal tract.The purpose of our article is to analyze the importance of antacid drugs in the market of the Republic of Kazakhstan. In this article, we will answer the questions of why antacids continue to be widely used in everyday practice, what new properties have been identi ed in these drugs, and what has allowed us to expand the range of indicators

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Antacids'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles